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Abstract
Natural	selection	acts	on	all	organisms,	including	parasites,	to	maximize	reproductive	
fitness.	Drug	resistance	traits	are	often	associated	with	 life-	history	costs	 in	 the	ab-
sence	of	treatment.	Schistosomiasis	control	programmes	rely	on	mass	drug	adminis-
tration	to	reduce	human	morbidity	and	mortality.	Although	hotspots	of	reduced	drug	
efficacy	have	been	reported,	resistance	is	not	widespread.	Using	Bayesian	state-	space	
models	(SSMs)	fitted	to	data	from	an	in vivo	laboratory	system,	we	tested	the	hypoth-
esis	 that	 the	spread	of	 resistant	Schistosoma mansoni	may	be	 limited	by	 life-	history	
costs	not	present	in	susceptible	counterparts.	S. mansoni	parasites	from	a	praziquantel-	
susceptible	(S),	a	praziquantel-	resistant	(R)	or	a	mixed	line	of	originally	resistant	and	
susceptible	 parasites	 (RS)	were	 exposed	 to	 a	 range	 of	 praziquantel	 doses.	 Parasite	
numbers	at	each	life	stage	were	quantified	in	their	molluscan	intermediate	and	murine	
definitive	hosts	 across	 four	generations,	 and	SSMs	were	used	 to	estimate	key	 life-	
history	parameters	for	each	experimental	group	over	time.	Model	outputs	illustrated	
that	parasite	adult	survival	and	fecundity	in	the	murine	host	decreased	across	all	lines,	
including	R,	with	increasing	drug	pressure.	Trade-	offs	between	adult	survival	and	fe-
cundity	were	observed	in	all	untreated	lines,	and	these	remained	strong	in	S	with	praz-
iquantel	pressure.	In	contrast,	trade-	offs	between	adult	survival	and	fecundity	were	
lost	under	praziquantel	pressure	in	R.	As	expected,	parasite	life-	history	traits	within	
the	molluscan	host	were	complex,	but	trade-	offs	were	demonstrated	between	para-
site	establishment	and	cercarial	output.	The	observed	trade-	offs	between	generations	
within	hosts,	which	were	modified	by	praziquantel	treatment	in	the	R	line,	could	limit	
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1  | INTRODUCTION
Parasite	populations	often	exhibit	 considerable	genetic	variability	 in	
their	natural	 tolerance,	or	 acquired	 resistance,	 to	drugs	 (Pollitt,	 Sim,	
Salathe,	 &	 Read,	 2015).	 Evolutionary	 theory	 suggests	 that	 one	 po-
tential	 mechanism	 for	 maintaining	 such	 diversity,	 particularly	when	
considering	 resistance,	 is	 fitness	 costs	 associated	 with	 such	 resis-
tance	 compared	 to	 susceptible	 lines	 (Hughes	 &	 Andersson,	 2015).	
The	 existence	 of	 life-	history	 costs	 and	 trade-	offs	 between	 them	 is	
supported	by	theoretical	and	empirical	studies	from	both	natural	and	
artificial	environments	across	a	wide	range	of	organisms	(Andersson	&	
Hughes,	2010;	Kempf	&	Zeitouni,	2009;	Koella	&	Antia,	2003;	Koella	
&	Zaghloul,	 2008).	However,	 convincing	demonstrations	of	 costs	of	
drug	 resistance	 within	 parasites	 and	 pathogens,	 and	 their	 underly-
ing	causes,	have	proved	elusive,	particularly	 in	animal	host–parasite	
systems.
Schistosomiasis	 is	a	debilitating	disease	caused	by	infection	with	
trematode	blood	flukes.	One	of	the	main	species	affecting	humans	is	
Schistosoma mansoni,	which	 causes	 intestinal	 schistosomiasis	 across	
sub-	Saharan	Africa	and	in	pockets	of	South	America	and	the	Middle	
East	 (GBD	2016).	Resistance	 to	praziquantel	 treatment	was	 first	 re-
corded in S. mansoni	 in	 the	mid-	1990s	 (Ismail	 et	al.,	1996,	1999).	 In	
2015,	61	million	people	were	treated	during	mass	drug	administration	
(MDA)	campaigns,	out	of	the	estimated	218	million	people	across	52	
countries	who	require	treatment	 (WHO	2016).	Despite	this	scale	of	
drug	pressure	and	a	number	of	reports	suggesting	reduced	praziquan-
tel	efficacy	in	response	to	MDA	(Black	et	al.,	2009;	Cioli	et	al.,	2004;	
Crellen	et	al.,	2016;	Danso-	Appiah	&	De	Vlas,	2002;	Lawn,	Lucas,	&	
Chiodini,	 2003;	Melman	 et	al.,	 2009;	Wang,	Wang,	 &	 Liang,	 2012),	
praziquantel	resistance	still	has	a	limited	recorded	distribution	(Botros	
et	al.,	2005;	Wang,	Dai,	Li,	Shen,	&	Liang,	2010;	Xu	et	al.,	2015).	Whilst	
observed	 low	 cure	 rates	 can	be	 caused	by	 a	 range	of	 factors	 other	
than	resistance,	such	as	high	intensities	of	infection,	high	rates	of	re-
infection,	 low	 drug	 absorption	 and	minimal	 previous	 immunological	
exposure	to	schistosomes,	cure	rates	in	some	areas	are	lower	than	ex-
pected	despite	taking	these	factors	into	consideration	(Danso-	Appiah	
&	De	Vlas,	2002).
A	 range	 of	 potential,	 not	 mutually	 exclusive,	 explanations	 have	
been	proposed	regarding	the	apparent	lack	of	emergence	and	estab-
lishment	of	praziquantel	true	resistance	to	date:	(i)	emergence	of	resis-
tance	may	be	slow	due	to	obligate	dioecious	sexual	reproduction	and	
a	diverse	complex	 life	cycle	 (Botros	&	Bennett,	2007);	 (ii)	 low	MDA	
coverage	and	untreated	 life	cycle	 stages	outside	of	 the	human	host	
provide	high	levels	of	refugia	for	susceptible	parasites	to	persist	(King,	
Muchiri,	&	Ouma,	2000;	Park,	Haven,	Kaplan,	&	Gandon,	2015);	 (iii)	
constraining	 selective	pressures	 from	concurrent	 snail	 control	 (King,	
Sutherland,	&	Bertsch,	2015;	Xu	et	al.,	2015);	or	(iv)	high	costs	of	resis-
tance	that	limits	their	transmission	and	fixation	capability	(Leathwick,	
2013;	William	et	al.,	2001).	One	early	mathematical	model	 indicated	
that	 praziquantel	 resistance	 could	 take	 over	 a	 decade	 to	 establish	
due	 to	 a	 combination	 of	 these	 limiting	 factors	 (King	 et	al.,	 2000).	
Widespread	 praziquantel	 resistance	 would	 undermine	 the	 current	
schistosomiasis	control	strategies,	as	there	are	currently	no	alternative	
accessible	drug	treatments.	Therefore,	it	is	important	to	gather	empir-
ical	evidence	to	support	or	refute	each	of	these	hypotheses,	to	inform	
appropriate	 interventions	 at	 a	 public	 health	 level.	 Such	 studies	 also	
help	understand	more	broadly	the	complex	processes	involved	in	the	
evolution	of	resistance	in	multihost	systems.
Here,	 using	 a	 laboratory	 host–parasite	 system,	 we	 explore	 the	
hypothesis	that	there	are	costs	associated	with	resistance	which	may	
act	to	limit	the	spread	of	praziquantel-	resistant	parasites.	Whilst	some	
S. mansoni	 isolates	can	maintain	resistance	in	the	 laboratory	without	
praziquantel	 pressure	 (Cioli	 et	al.,	 2004),	 other	 S. mansoni	 isolates	
have	been	reported	to	revert	to	susceptibility	in	as	few	as	six	mouse	
passages	without	 treatment	 (William	et	al.,	2001).	 In	 the	absence	of	
drug	pressure,	praziquantel-	resistant	S. mansoni	 lines	can	have	lower	
cercarial	production	relative	to	their	susceptible	counterparts	(William	
et	al.,	2001).	However,	there	are	inconsistencies	across	resistant	lines,	
with	some	lines	having	lower	adult	worm	establishment	and	fecundity	
compared	 with	 praziquantel-	susceptible	 lines	 (William	 et	al.,	 2001).	
Reversion	to	susceptibility	and	evidence	of	costs	in	definitive	hosts	for	
some	resistant	lines	provide	support	that	life-	history	costs	could	act	to	
limit	the	spread	of	those	resistant	lines.	However,	more	experimental	
studies	are	needed	 to	explicitly	measure	 these	differences	between	
lines	and	how	these	vary	under	selection	pressures.
We	combined	a	snail	and	mouse	laboratory	study	with	statistical	
modelling	to	elucidate	the	life-	history	traits,	and	trade-	offs	between	
these	 traits,	 across	 varying	 doses	 of	 in vivo	 praziquantel	 in	 drug-	
susceptible,	drug-	resistant	and	mixed	 (50%	susceptible	and	50%	re-
sistant)	S. mansoni	lines	across	four	parasite	generations.	We	test	the	
hypotheses	that	(i)	costs	associated	with	praziquantel	resistance,	dis-
played	within	either	the	intermediate	or	definitive	host	stage,	would	
reduce	 the	 overall	 fitness	 of	 the	 line	 relative	 to	 its	 susceptible	 or	
mixed-	selected	counterparts	in	the	absence	of	drug	pressure,	and	that	
the	spread	of	R	parasites	under	praziquantel	pressure.	Whilst	such	complex	life-	history	
costs	may	be	difficult	 to	detect	using	 standard	empirical	methods,	we	demonstrate	
that	SSMs	provide	robust	estimates	of	life-	history	parameters,	aiding	our	understand-
ing	of	costs	and	trade-	offs	of	resistant	parasites	within	this	system	and	beyond.
K E Y W O R D S
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net	costs	would	be	dependent	on	both	(ii)	praziquantel	dose	and	(iii)	
selection	generation.
2  | MATERIALS AND METHODS
2.1 | Experimental design
For	the	selection	experiment,	full	details	of	the	experimental	method-
ology	are	described	in	Lamberton,	Faust,	and	Webster	(2017).	Briefly,	
there	were	nine	treatment	groups	in	a	full-	factorial	design	with	three	
S. mansoni	 parasite	 lines	 (praziquantel-	resistant	 (R),	 susceptible	 (S)	
and	mixed	 infection	 (RS:	 50%	R	 and	50%	S	 in	 the	 first	 generation))	
and	three	praziquantel	doses	administered	to	mice	(control—sham	2%	
cremophor	EL;	low—25	mg/kg	praziquantel	diluted	in	2%	cremophor	
EL;	high—50	mg/kg	praziquantel	in	2%	cremophor	EL).	Both	doses	of	
praziquantel	were	subcurative	for	all	parasite	lines	to	ensure	long-	term	
maintenance	of	 the	 line.	 Parasites	 from	each	 treatment	 group	were	
maintained	for	four	generations	 (G1–G4),	using	four	definitive	hosts	
(female	Tuc	Ordinary	(TO)	Harlan®	adult	mice)	and	50	indeterminate	
hosts	(30	Biomphalaria glabrata and 20 B. alexandrina)	in	each	genera-
tion	(Figure	1a	and	Appendix	Fig.	S1).
2.1.1 | Observational parasite life- history data
Mice	were	exposed	to	a	fixed	number	of	cercariae	(220	in	G1	and	then	
110	in	G2–G4	due	to	minor	mouse	morbidity	in	G1)	from	the	selection	
line.	6	weeks	(42	days)	after	exposure	to	cercariae,	mice	were	orally	
gavaged	with	control,	low	or	high	doses	of	praziquantel.	Between	49	
and	62	days	postexposure,	mice	were	euthanized	and	adult	schisto-
somes	counted	following	collection	with	a	modified	hepatic	perfusion	
technique	(Smithers	&	Terry,	1965).	An	exception	occurred	at	day	42	
in	G1	when	two	mice	from	the	low-	dose	R	treatment	arm	became	ill	
and	had	to	be	euthanized	earlier.	Counts	of	adult	schistosomes	were	
also	collected	for	these	mice.	Eggs	obtained	from	the	liver	and	spleen	
of	each	mouse	were	washed	in	saline	as	described	in	Lamberton	et	al.	
(2017)	and	placed	in	direct	light	in	70	ml	spring	water	for	1	hr	to	induce	
hatching	of	miracidia.	Estimates	of	viable	miracidia	were	obtained	by	
counting	the	number	of	miracidia	in	ten	0.2-	ml	samples	per	mouse.
F IGURE  1 Simplified	experimental	design	and	life	cycle	of	S. mansoni	(as	modelled).	(a)	Each	parasite	line	(S,	R	and	RS)	was	maintained	in	
the	laboratory	through	passage	in	four	mice	and	50	snails	in	each	generation	for	each	praziquantel	treatment	regime.	In	generation	1	(G1),	
mice	were	infected	with	220	cercariae,	and	in	subsequent	generations	(G2–G4),	110	cercariae	were	used	to	infect	mice.	In	all	generations,	six	
miracidia	were	used	to	infect	snails.	(b)	The	life	cycle	of	schistosomes	was	modelled	using	particular	life	stages.	Cercariae	(C)	enter	the	definitive	
mouse	host	and	establish	themselves	as	adults	(A).	Those	adults	that	survive	(with	survival	rate	sa)	will	sexually	reproduce	and	lay	eggs	with	a	
rate	λ,	which	hatch	into	miracidia	(M).	The	miracidia	that	survive	(with	a	rate	sm)	will	then	leave	the	mouse	host	and	enter	the	snail.	The	miracidia	
(M)	establish	inside	the	intermediate	snail	host	with	a	rate	θ	and	will	start	shedding	sporocysts	that	become	cercariae	(C)	at	a	rate	ϕ. A new 
generation	will	begin	as	the	new	cercariae	enter	the	definitive	host.	The	parameters	in	red	correspond	to	those	which	can	be	impacted	by	
praziquantel.	The	dotted	arrows	indicate	steps	that	occurred	through	experimental	manipulation.	The	schistosome	images	are	modified	with	
permission	from	Genome	Research	Limited	(https://www.yourgenome.org/facts/what-is-schistosomiasis)
(a)
(b)
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To	 initiate	 the	 asexual	 stage	 of	 the	 schistosome	 life	 cycle,	 50	
Biomphalaria	 snails	 (30	 B. glabrata and 20 B. alexandrina)	 per	 treat-
ment	group	in	5	ml	spring	water	were	each	exposed	to	six	miracidia	
that	were	pooled	 from	all	mice	within	 the	same	experimental	 treat-
ment	group.	Miracidia	remaining	after	2	hr	of	exposure	were	counted	
and	discarded.	Snail	 survival	was	 recorded	weekly.	Each	week,	 from	
3	weeks	post-	parasite	exposure	(to	allow	for	maturation	of	sporocysts	
and	 subsequent	 cercarial	 production	 (Rollinson	 &	 Johnston,	 1996)),	
snails	were	placed	in	the	dark	for	24	hr	and	then	exposed	to	2	hr	of	
light,	at	11	a.m.,	in	glass	vials	containing	16	ml	spring	water,	to	prompt	
cercarial	shedding.	The	number	of	cercariae	was	estimated	in	two	0.2-	
ml	aliquots	per	snail.	Due	to	variation	in	the	number	of	shedding	snails,	
which	may	have	been	influenced	by	factors	external	to	the	experimen-
tal	 treatments,	 cercariae	were	pooled	 from	 ten	 snails	 (including	any	
B. alexandrina	where	possible)	at	10	weeks	postexposure	to	 improve	
consistency	between	treatment	groups	and	generations.	These	were	
then	used	to	infect	the	next	generation	of	mice.	This	protocol	was	con-
tinued	until	generation	four	(G4)	(Figure	1a	and	Appendix	S1	Fig.	S1).	
Raw	data	for	this	experiment	are	shown	in	Figure	2	and	Appendix	S2	
Fig.	S2.
2.2 | Parasite life cycle state- space model
To	understand	the	complexities	governing	potential	variation	in	life-	
history	 traits	 and	 trade-	offs	 in	 S. mansoni	 parasite	 lines,	 and	 how	
these	may	be	impacted	by	low	and	high	praziquantel	doses,	we	mod-
elled	the	life	cycle	of	the	three	lines	of	S. mansoni	across	generations.	
We	 developed	 two	 Bayesian	 stage-	structured	 population	 models	
implemented	within	a	 state-	space	modelling	 (SSM)	 framework.	The	
first	model	emulated	the	sexual	portion	of	the	worm	life	cycle	inside	
the	definitive	mouse	host.	The	second	model	 recreates	 the	asexual	
portion	of	the	life	cycle	inside	the	intermediate	snail	host.	Figure	1b	
illustrates	 the	stages	of	 the	worm	 life	cycle	as	 they	were	modelled	
and	 how	 each	 stage	 relates	 to	 the	 experimental	 data	 described	 in	
Figure	1a.	Two	independent	models	were	implemented	as	the	tran-
sition	between	hosts	was	experimentally	manipulated;	that	 is,	there	
were	not	natural	population	dynamics	between	hosts	or	generations;	
for	 example,	 each	 snail	 was	 exposed	 to	 a	 fixed	 six	miracidia	 (indi-
cated	by	dotted	lines	in	Figure	1).	We	chose	a	state-	space	model	ap-
proach	because	it	inherently	recognizes	that	the	observation	process	
(as	determined	here	by	the	experimental	design,	sampling	and	data	
collection	protocols)	 is	not	a	direct	mirror	of	 the	biological	process	
(the	 parasite’s	 life	 cycle)	 underlying	 the	 creation	 of	 these	 observa-
tions	(e.g.,	our	observations	are	partial	counts	of	the	true	miracidia/
worm/cercariae	numbers)	and	that	the	reconstruction	of	this	biologi-
cal	process	requires	integration	of	both	these	processes	(Harvey	et	al.	
2004).	Furthermore,	the	ability	to	use	priors	based	on	previous	stud-
ies	 strengthens	 our	 inference.	 Finally,	 similar	model	 structures	 can	
be	used	for	both	the	sexual	and	asexual	component	of	the	life	cycle,	
which	 facilitates	 interpretations	 of	 the	 results	 across	 the	 parasites’	
entire	life	cycle.
2.2.1 | Within- mouse model
The	sexual	 life	cycle	model	starts	with	cercariae	(C)	establishment	
inside	the	mouse.	After	establishment,	cercariae	develop	into	adults	
(A)	 and	 the	adults	 that	 survive	 can	 reproduce	and	 lay	eggs.	Once	
exposed	 to	 freshwater,	 these	 eggs	 hatch	 into	miracidia	 (M).	With	
the	within-	mouse	model	 (Figure	1),	we	estimate	the	adult	survival	
(sA)	 and	 fecundity	 (λ)	 rates	 for	 each	 parasite	 line	 across	 the	 four	
F IGURE  2 Raw	data	counts	of	Schistosoma mansoni	in	the	different	life	cycle	stages	for	each	parasite	line	(symbols:	S	susceptible;	R:	resistant;	
RS:	resistant–susceptible)	and	praziquantel	treatment	group	(colours).	Average	number	(±standard	deviation)	of	(a)	adult	worms	per	cercaria	
and	(b)	miracidia	per	adult	worm/day	and	(c)	the	weekly	number	of	cercariae	produced	per	miracidium	(right)	are	estimated	across	the	four	
generations	for	each	line/treatment	group
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generations	and	the	impact	of	low	and	high	praziquantel	doses	on	
these	 two	 traits.	 Specifically,	 we	 model	 the	 number	 of	 cercariae	
in	replicate	 i	from	generation	t	that	became	established	inside	the	
mouse	 and	 survived	 to	 full	 adult,	 nA,i,t	 as	 a	 binomial	 process	 pa-
rameterized	 by	 the	 number	 of	 cercariae	 each	 mouse	 is	 exposed	
to	 (nA,i,t = 220 in t = 1 and nA,i,t = 110 in t	=	2,3,4)	 and	 probability	
sA,i,t	describing	the	combined	establishment	and	adult	survival	rate	
(Figure	1),	which	was	expressed	as	a	 logit	 function	of	 low	or	high	
drug	dose:
The	baseline	daily	 survival	of	each	parasite	 line	 (l)	β0,l	was	given	
a	prior	distribution	derived	from	a	beta	distribution	with	mean	0.85	
and	variance	0.01	 (transformed	 to	 the	 logit	 space;	 see	derivation	 in	
Appendix	S3	Table	S1).	The	prior	 is	 lower	 than	 typical	daily	 survival	
rates	to	account	for	low	establishment	(Smithers	&	Terry,	1965),	but	
the	variance	is	wide	enough	to	capture	values	of	1	or	near	0.	The	coef-
ficients	β1,l,t and β2,l,t	governing	the	impact	of	low	and	high	treatment	
in	each	parasite	line	 l	and	generation	t	were	estimated	using	normal	
distribution	priors	with	mean	0	and	precision	0.01;	hence,	the	impact	
of	praziquantel	on	survival	can	be	positive	or	negative.	The	praziquan-
tel	doses	were	modelled	as	binary	switches	(i.e.,	whether	a	replicate	
was	exposed	to	high	(Highi,t	=	1,	Lowi,t	=	0),	low	(Highi,t	=	0,	Lowi,t	=	1)	
or	no	praziquantel	 (Highi,t	=	0,	Lowi,t	=	0)	dose	to	facilitate	computa-
tion	of	these	separate	treatments	in	each	parasite	line	and	generation).	
Hence,	here	the	adult	survival	rate	is	a	combination	of	the	adult	worm	
survival	and	the	establishment	rate	of	the	cercariae	inside	the	mouse,	
and	the	baseline	β0,l	refers	to	the	survival	of	control	individuals	from	
each	line,	that	is,	those	that	were	not	exposed	to	any	treatment	in	any	
generation.
The	 adults	 then	 reproduce,	 and	 the	 number	 of	miracidia	 (nM0,i,t)	
emerging	per	replicate	i	and	generation	t	is	estimated	as	a	function	of	
the	fecundity	rate	λi,t	(Figure	1),	the	number	of	adult	worms	nA,i,t and 
the	adult	survival	rate	sA,i,t:
Similar	 to	 the	 survival	 rate,	 the	 fecundity	 rate	 λi,t	 was	 also	 ex-
pressed	as	a	function	of	praziquantel	dose:
where	λ0,l	corresponds	to	the	baseline	daily	fecundity	rate	of	each	
line	and	was	modelled	with	a	normal	prior	distribution	with	a	mean	
defined	as	the	average	number	of	eggs	laid	per	day	(n	=	365;	Loker	
(1983))	per	worm	pair,	of	which	34%	mature	to	miracidia	(Chamez,	
2006)	 (mean	=	365*0.5*0.34	=	62.05);	 that	 is,	 the	 fecundity	 rate	
is	 an	estimate	of	 the	number	of	eggs	 laid	by	one	unexposed	pair	
of	worms	 that	 hatch	 and	 become	miracidia.	The	 coefficients	λ1,l,t 
and λ2,l,t	governing	the	impact	of	low	and	high	treatment	were	es-
timated	 using	 normal	 distribution	 priors	with	 mean	 0	 and	 preci-
sion	0.01,	 and	praziquantel	 doses	were	 again	modelled	 as	 binary	
switches.
Because	the	mice	were	not	all	sacrificed	at	the	same	time,	worms	
that	stayed	alive	longer	during	the	experiment	were	likely	to	have	laid	
more	 eggs	 during	 their	 lifetime.	We	 deal	with	 this	 potential	 bias	 in	
worm	counts	by	weighting	the	number	of	adults	nA,i,t	by	a	summation	
of	survival	sA,i,t	across	the	number	of	days	mature	reproducing	worms	
were	alive	in	each	replicate	ΔT,	which	ranges	from	T	=	1,	that	is	day	42	
when	the	first	mouse	was	culled	and	miracidia	counted,	to	x	=	20	days,	
that	is	day	62	when	the	last	mouse	was	culled.	This	allowed	to	esti-
mate	the	cumulative	fecundity	of	worms	over	their	mature	lifespan	in	
the	mouse.
The	number	of	miracidia	that	survive	nM,i,t	was	modelled	as	a	bi-
nomial	process	of	nM0,i,t	and	probability	sM,i,t	describing	the	miracidia	
survival	 rate	expressed	as	a	 logit	 function	of	a	parasite	 line-	specific	
baseline	 assuming	 a	 prior	 based	on	 a	 logit	 of	 a	 beta	 distribution	 of	
mean 0.85 and variance 0.01.
Finally,	the	number	of	miracidia	in	the	mouse	was	estimated	based	
on	the	observed	data	by	modelling	it	as	a	binomial	process	of	the	num-
ber	of	miracidia	that	survived	nM,i,t	and	the	proportion	p	of	miracidia	in	
the	population	that	were	counted.	Given	that	we	have	no	estimates	of	
the	proportion	of	miracidia	we	can	observe,	the	parameter	p	was	esti-
mated	using	an	uninformative	uniform	prior	distribution	ranging	from	
0	to	1.	Similarly,	 the	total	number	of	adults	observed	 (observational	
data)	is	modelled	as	a	binomial	process	of	the	number	adult	that	sur-
vived nA,i,t	and	the	proportion	q	that	are	counted.	Perfusion	techniques	
enable	 accurate	 quantification	 and	 identification	 for	 schistosomes;	
hence,	the	parameter	q	was	estimated	using	a	beta	distribution	prior	
with	mean	0.9	and	variance	0.01.
2.2.2 | Within- snail model
The	asexual	stage	of	the	life	cycle	starts	with	miracidia	establishment	
inside	the	snail	host.	Once	established,	the	miracidia	that	survive	de-
velop	into	sporocysts	which	asexually	reproduce	and	grow	into	cer-
cariae.	In	the	within-	snail	model,	we	estimated	the	miracidia	infectivity	
and	cercarial	shedding	rates	across	the	four	generations	(Figure	1)	and	
explore	the	impact	of	praziquantel	dose	in	the	previous	mouse	host	on	
the	cercarial	shedding	rate.
The	 within-	snail	 model	 is	 similar	 to	 the	 within-	mouse	 model.	
Specifically,	 the	 number	 of	miracidia	which	 established	 nMe,i,t	 inside	
each	snail	replicate	i	from	generation	t	was	modelled	as	a	binomial	pro-
cess	parameterized	with	the	number	of	miracidia	the	mouse	was	ex-
posed	to	(n	=	6)	and	the	establishment	rate	θi,t.	In	turn,	θi,t	is	expressed	
as	a	logit	function	of	the	baseline	establishment	rate	of	each	parasite	
line	and	generation	using	a	prior	derived	from	a	beta	distribution	with	
mean 0.85 and variance 0.01.
Once	established,	 the	average	weekly	number	of	 cercariae	nC0,i,t 
emerging	per	replicate	i	and	generation	t	is	estimated	as	a	function	of	
the	cercarial	shedding	rate	ϕi,t,	and	the	number	of	miracidia	entering	
into	the	snail:
(1)logit(sA,i,t)=β0,l−β1,l,tLowi,t−β2,l,tHighi,t
(2)nM0,i,t=λi,t ∗nA,i,t ∗
x∑
T=1
sA,i.t
ΔT
(3)λi,t=λ0,l−λ1,l,tLowi,t−λ2,l,tHighi,t
(4)nM,i,t∼B(nM0,i,t,SM,i,t)
(5)nC0,i,t=ϕi,t ∗nM,i,t
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The	miracidia	 develop	 into	 and	 shed	 cercariae	with	 an	 average	
weekly	rate	ϕi,t,	which	was	modelled	following	equation	(3),	with	the	
prior	for	the	baseline	shedding	rate	for	each	line	and	generation	de-
rived	 from	a	gamma	distribution	parameterized	with	mean	200	and	
variance	1000.	The	coefficients	governing	the	impact	of	low	and	high	
treatment	were	modelled	also	from	a	gamma	distribution	with	mean	
0.1 and variance 0.01.
Finally,	 the	 number	 of	 cercariae	 in	 the	 snail	 nC,i,t	was	 estimated	
based	on	the	observed	data	by	modelling	it	as	a	binomial	process	of	
the	number	cercariae	that	survived	nC0,i,t	and	the	proportion	P	of	ob-
served	cercariae,	which	is	estimated	using	an	uninformative	uniform	
prior	distribution	ranging	from	0	to	1.	Appendix	S3	Table	S1	summa-
rizes	the	priors	used	in	both	models	and	provides	an	example	of	a	prior	
derivation	for	the	logit	space.
2.2.3 | Model fitting
The	model	was	fitted	using	the	softwares	R	and	JAGS	(Plummer,	2003),	
and	two	chains	were	run	until	full	convergence	was	achieved	in	all	pa-
rameters;	that	is,	from	106	iterations	run,	the	first	half	were	discarded	
and	 every	 100th	 iteration	 kept	 for	 analysis	 (thinning).	 Convergence	
was	assessed	 through	visual	 inspection	of	 the	 trace	plots	as	well	as	
using	the	Heidelberg	diagnostic	test.	Model	performance	was	further	
assessed	through	the	model	 fit	 (i.e.,	similarity	between	observations	
and	model	estimates;	see	Appendix	S3	Figs	S3–S5)	and	congruence	
between	 prior	 and	 posterior	 distributions	 (posterior	 distribution	
should	be	narrower	but	fall	within	the	prior	distribution).
3  | RESULTS
The	results	of	the	SSMs	were	used	to	address	our	three	hypotheses.	
Firstly,	the	differences	in	the	life-	history	traits	of	the	controls	(base-
lines)	estimated	for	each	parasite	line	(S,	RS	and	R)	enable	identifica-
tion	of	fitness	costs	and	the	net	fitness	associated	with	praziquantel	
resistance.	 Net	 fitness	 was	 estimated	 within	 each	 generation	 and	
evaluated	as	 the	 trade-	off	between	adult	worm	survival	and	 fecun-
dity	in	the	mouse	host	and	miracidia	establishment	and	cercarial	pro-
duction	in	the	snail	host.	Secondly,	the	comparison	of	these	traits	in	
the	control	groups	with	those	in	the	presence	of	low	and	high	doses	
of	praziquantel	shows	how	fitness	 is	 impacted	by	praziquantel	dose	
administrated	 to	 the	definitive	host.	Thirdly,	 to	 investigate	whether	
there	was	selection	for	resistance	under	drug	pressure,	the	individual	
traits	 within	 each	 line	 and	 treatment	 group	were	 compared	 across	
generations.	Our	parasite	life	cycle	models	provided	a	good	fit	to	the	
data	observed	 (Fig.	S2)	and	converged	appropriately,	supporting	ro-
bustness	of	the	model	and	estimated	life-	history	parameters.
3.1 | Life- history traits but not trade- offs differ 
between parasite lines in control groups
In	the	untreated	control	groups,	the	number	of	observed	adult	worms,	
miracidia	 and	 cercariae	 differed	 between	 parasite	 lines	 (Figure	2).	
The	RS	line	had	the	greatest	overall	fitness	with	the	highest	number	
of	worms	per	cercaria,	the	highest	miracidia	per	adult	worm	and	the	
highest	cercariae	per	miracidium	in	B. glabrata	snails.	In	the	sympatric	
B. alexandrina	snails,	however,	RS	had	the	 lowest	observed	cercarial	
production.	These	counts	were,	nevertheless,	variable	between	gen-
erations	(Appendix	S2	Fig.	S2).
In	 the	definitive	host,	 the	adult	survival	 rate	estimated	from	the	
life	cycle	model	is	a	combination	of	the	adult	worm	survival	and	the	
establishment	rate	of	the	cercariae	inside	the	mouse	host.	The	average	
survival	of	S	worms	was	the	most	variable	across	generations,	ranging	
from	0.51	in	G3	to	0.80	worms/cercaria	in	G4,	and	was	generally	lower	
compared	to	other	lines	(Table	1;	Figure	3a–c,	x-	axis).	For	example,	the	
average	 survival	 across	generations	 in	S	 line	was	0.65	and	 in	R	 line	
was	0.71.	RS	parasites	had	the	most	similar	rates	of	adult	worm	sur-
vival	 between	 generations,	with	 an	 average	of	 0.77	worms/cercaria	
(Figure	3b).	The	estimated	fecundity	rate	for	control	groups	was	highly	
variable	across	our	experimental	conditions,	ranging	from	40	(R,	G3)	to	
127	(R,	G1)	viable	miracidia/worm/day	depending	on	generation	and	
parasite	line	(Table	1;	Figure	3a–c,	y-	axis).	However,	the	fecundity	rate	
of	control	R	worms	was	generally	higher,	with	a	mean	across	genera-
tions	of	104	miracidia/worm/day,	compared	to	95	and	91	miracidia/
worm/day	in	S	and	RS	lines,	respectively.	Negative	trade-	offs	between	
survival	 and	 fecundity	 rates	 were	 estimated	 for	 all	 control	 groups	
among	 all	 parasites	 lines,	with	 fecundity	 decreasing	with	 increasing	
adult	worm	survival	(Figure	3a–c,	black	line).
The	results	from	the	intermediate	host	model	(Figure	3d–i)	show	that	
the	establishment	rates	of	miracidia	in	the	untreated	controls	were	highly	
variable,	but	similar	among	parasite	 lines	and	between	snail	host	spe-
cies,	ranging	between	0.5	and	1	(Figure	3d–i,	x-	axis).	In	contrast,	the	es-
timated	weekly	cercarial	shedding	rates	in	the	untreated	control	groups	
differed	greatly	between	the	two	snail	species	 (Figure	3d–i,	y-	axis),	al-
though	no	pattern	across	generation	or	parasite	line	was	identified.	The	
overall	cercariae	shedding	rate	was	lower	and	less	consistent	in	B. alexan-
drina	compared	with	B. glabrata	(e.g.,	in	RS	B. alexandrina ~0–300; B. gla-
brata	~200–400	cercariae).	However,	the	data	obtained	in	B. alexandrina 
were	highly	variable	across	generations	and	 lines,	as	 large	numbers	of	
snails	did	not	survive	once	patent,	which	may	have	interfered	with	the	
estimation	of	the	shedding	rates.	Regardless,	in	B. alexandrina,	our	results	
demonstrated	 a	 clear	 trade-	off	 between	 establishment	 and	 shedding	
rates,	where	higher	 establishment	 rates	 led	 to	 lower	 cercariae	output	
(Figure	3g–i,	black	lines).	However,	these	trade-	offs	were	not	strong	for	
either	R	or	S	lines	when	infecting	B. glabrata	(Figure	3d,	f,	black	lines).
3.2 | Praziquantel dose- dependent changes in life- 
history traits and trade- offs in definitive hosts
In	the	definitive	host,	the	observed	data	from	the	experiments	dem-
onstrated	that	treatment	with	praziquantel	lowers	the	number	of	adult	
worms/cercaria	and	miracidia/adult	worm	across	the	three	S. mansoni 
lines	(Figure	2a,b).	The	data	from	the	snail	experiments	demonstrated	
that	praziquantel	 treatment	 in	 the	previous	mouse	host	did	not	 im-
pact	 the	 average	 number	 of	 cercariae/miracidium	 neither	 in	 snail	
species	(Figure	2c)	nor	across	generations	(Appendix	S2	Fig.	S2).	Our	
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models	 confirmed	 these	 observations.	 Specifically,	 the	 within-	snail	
model	estimated	a	negligible	impact	of	praziquantel	on	cercarial	pro-
duction.	 It	 is	possible	 that	praziquantel	 impacted	cercarial	output	 in	
some	line:generation	combinations;	however,	the	improved	model	fit	
in	the	absence	of	these	effects,	and	the	inconsistency	of	its	magnitude	
across	the	replicates,	does	not	provide	enough	evidence	to	conclude	
that	 praziquantel	 treatment	 in	 the	 mouse	 host	 can	 affect	 cercarial	
output	 in	the	current	snail	host.	Because	the	effects	of	praziquantel	
exposure	in	the	sexual	life	cycle	stage	do	not	appear	to	carry	through	
to	the	asexual	life	cycle	stage,	this	suggests	that	S. mansoni	parasites	
are	not	impacted	by	indirect	exposure	to	praziquantel.	In	this	section,	
we	therefore	focus	on	the	impacts	of	praziquantel	dose	on	the	sexual	
life-	history	parameters	of	schistosomes	in	the	definitive	mouse	host.
The	results	from	the	within-	mouse	model	suggest	that	S	lines	were	
more	impacted,	in	terms	of	fecundity	reduction,	by	praziquantel	than	
R	or	RS	lines	(Figure	4	compared	to	Figure	3a–c;	Table	1).	Indeed,	fe-
cundity,	and	to	a	lesser	extent	survival,	was	consistently	impacted	by	
50	mg/kg	praziquantel	although	with	varying	magnitudes	across	gener-
ations	(Table	1).	Trade-	offs	between	survival	and	fecundity	in	S-	treated	
lines	were	similar	to	control	untreated	lines,	with	fecundity	decreasing	
with	increasing	adult	worm	survival.	In	R	lines,	adult	survival	was	most	
negatively	 impacted	 by	 50	mg/kg	 praziquantel	 compared	 to	 other	
lines,	but	 fecundity	was	 least	 affected	at	 the	 same	dosage	 in	nearly	
every	 generation	 (Table	1).	The	 net	 impact	 of	 praziquantel	 on	 these	
traits	led	to	a	lack	of	clear	trade-	offs	between	fecundity	and	survival	
(Figure	3c,f),	suggesting	the	life-	history	strategies	are	changed	in	these	
R	lines	even	in	the	presence	of	low	praziquantel	doses.	Interestingly,	in	
the	RS	line	this	change	in	trade-	offs	only	occurs	in	the	presence	of	the	
higher	50mg/kg	praziquantel	dose	(Figure	4e).	This	is	consistent	with	
its	anticipated	lower	level	of	resistance	compared	with	the	R	line,	but	
higher	level	of	resistance	compared	with	the	S	line	(Figure	4).
3.3 | Evidence of selection during the experiment
Our	within-	mouse	model	 showed	 that	 praziquantel	 treatment	 low-
ered	 worm	 density	 by	 impacting	 both	 adult	 survival	 and	 fecundity	
in	all	parasite	 lines	 (Table	1	and	Figure	4).	However,	 the	 lack	of	de-
crease	with	continued	praziquantel	dose	across	generations	suggests	
that	resistance	across	generations	was	not	further	selected	for.	Our	
within-	snail	model	shows	there	was	positive	selection	for	miracidia	in-
fectivity	in	B. glabrata,	as	seen	by	the	increasing	establishment	rate	of	
miracidia	of	all	lines	across	generations:	from	0.6	in	G1	to	~1.0	in	G4	
Susceptible
Resistant–
Susceptible Resistant
Survival
Baseline	(control) G1 0.62	(0.59–0.75) 0.71	(0.66–0.80) 0.65	(0.57–0.86)
G2 0.70	(0.62–0.79) 0.77	(0.70–0.91) 0.66	(0.60–0.84)
G3 0.51	(0.40–0.71) 0.78	(0.74–0.87) 0.89	(0.85–0.93)
G4 0.80	(0.74–0.90) 0.81	(0.77–0.90) 0.65	(0.61–0.74)
%	Reduction	low	
praziquantel
G1 29.86	(22.7–37.3) 38.97	(33.0–45.1) 30.09	(19.1–42.3)
G2 25.33	(15.4–35.8) 19.86	(13.1–26.5) 28.86	(20.2–38.2)
G3 9.05	(0.0–20.1) 23.01	(16.9–28.9) 44.58	(33.5–54.0)
G4 21.10	(13.4-	29.0) 9.65	(0.0–19.5) 0	(0–1.1)
%	Reduction	high	
praziquantel
G1 53.24	(44.0–59.3) 8.88	(0.4–17.5) 52.39	(42.2–59.3)
G2 30.63	(17.6–39.7) 31.74	(23.2–39.4) 48.84	(37.5–57.6)
G3 8.17	(0.0–19.7) 22.69	(16.1–29.7) 49.19	(42.1–55.7)
G4 12.54	(2.3–23.0) 19.43	(12.6–25.2) 40.48	(32.5–47.7)
Fecundity
Baseline	(control) G1 123	(105–141) 117	(101–134) 127	(114–141)
G2 65	(53–81) 89	(70–111) 120	(107–140)
G3 115	(94–136) 75	(55–98) 40	(33–54)
G4 77	(69–86) 85	(70–108) 129	(110–149)
%	Reduction	low	
praziquantel
G1 27.69	(17.97–36.81) 0.0	(0.0–0.0) 0.0	(0.0–5.38)
G2 0.0	(0.0–8.59) 2.97	(0.0–17.05) 4.34	(0.0–16.20)
G3 0.0	(0.0–5.99) 0.0	(0.0–0.0) 0.0	(0.0–0.0)
G4 31.02	(13.81–46.57) 40.76	(27.74–53.53) 0.0	(0.0–8.41)
%	Reduction	high	
praziquantel
G1 4.98	(0.0–14.11) 42.30	(31.13–50.78) 14.58	(2.28–23.03)
G2 44.21	(26.83–58.00) 21.79	(2.46–36.21) 10.56	(0.0–19.11)
G3 3.78	(0.0–17.11) 21.35	(9.84–34.56) 37.29	(24.45–50.80)
G4 71.07	(60.65–76.95) 17.06	(1.59–35.31) 14.30	(1.80–24.93)
TABLE  1 SSM	estimated	key	sexual	
life-	history	parameters.	Median	(95%	CIs)	
adult	survival	and	fecundity	rates	baselines	
(i.e.,	control	groups)	and	the	percentage	of	
reduction	over	that	baseline	caused	by	low	
and	high	doses	of	praziquantel	in	each	
generation	and	line
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(Figure	3d–f,	x-	axis).	In	B. alexandrina,	the	establishment	rate	was	low	
in	G1	but	was	equally	high	(near	1)	in	the	following	three	generations.
4  | DISCUSSION
Understanding	 changes	 in	 life-	history	 traits	 and	 potential	 costs	 of	
drug	resistance	in	parasites	is	important	for	managing	the	emergence	
of	resistance	and	implementing	suitable	control	measures	in	regions	
where	resistance	 is	 found.	 In	this	study,	we	use	state-	space	models	
(SSMs)	to	quantify	these	costs	using	empirical	data	from	a	laboratory	
study	of	 an	 indirectly	 transmitted	parasite.	We	show	 that	 it	 is	pos-
sible	to	measure	differences	in	life-	history	traits	in	parasite	suscepti-
ble	and	resistant	lines,	providing	a	proof	of	concept	for	implementing	
these	 techniques	 in	other	parasites	with	complex	 life	cycles.	Whilst	
we	observed	a	large	variation	in	S. mansoni	life-	history	traits	between	
F IGURE  3 Untreated	control	(baseline)	life-	history	traits	and	trade-	offs	in	the	definitive	(a–c)	and	intermediate	(d–i)	hosts.	For	each	
Schistosoma mansoni	line,	susceptible	(S;	left),	mixed	resistant	and	susceptible	(RS;	middle)	and	resistant	(R;	right),	the	median	(with	95%	CIs)	life-	
history	traits	(x-	and	y-	axis)	are	shown	for	each	generation.	The	trade-	offs	between	traits	(black	line	and	associated	slope,	β)	were	obtained	from	
a	Poisson	GLM	of	the	posterior	distributions	of	survival	(a–c)	or	establishment	(d–i)	rates	against	those	of	fecundity	(a–c)	or	shedding	(d–i)	rates,	
respectively.	All	regressions	were	significant	with	p<.001. p-	values	and	standard	deviations	shown	in	Appendix	S3	Table	S2
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praziquantel-	treated	 groups	 and	 across	 generations,	 the	 parameter	
estimates	generated	from	the	model	enabled	us	to	show	that	variation	
between	groups	can	be	better	understood	when	shown	as	life-	history	
trade-	offs.	 Higher	 fecundity	 in	 untreated	 parasites	 was	 associated	
with	 lower	 survival	 within	 the	 same	 generations,	meaning	 that	 net	
fitness	was	similar	to	untreated	parasites	in	another	generation	that	
had	 lower	fecundity	but	higher	survival	 in	the	definitive	host	of	the	
same	line	(Figure	5a).	However,	when	adult	worms	were	exposed	to	
praziquantel,	 trade-	offs	 between	 fecundity	 and	 survival	 in	 low	 and	
high	treated	R	groups	and	high	treated	RS	groups	were	no	longer	ob-
served.	This	suggests	that	R,	and	to	some	extent	RS,	respond	to	drug	
pressure	by	altering	resource	allocation,	affecting	observations	of	life-	
history	trade-	offs	 (Figure	5b).	Whilst	this	does	not	explicitly	provide	
support	 for	 the	hypothesis	 that	 costs	of	 resistance	 limit	 the	 spread	
of	 praziquantel-	resistant	 phenotypes	 in	 natural	 populations,	 it	 does	
suggest	that	life	histories	are	altered	in	R	parasites	when	exposed	to	
praziquantel,	but	not	altered	in	the	S	parasite	lines.
Using	 a	 S. mansoni	 model,	 our	 findings	 indicate	 that	 measur-
ing	 within-	host	 parasite	 life-	history	 trade-	offs	 captures	 better	 the	
complexity	 of	 host–parasite	 interactions	 which	 are	 affected	 by	
praziquantel,	than	empirical	measures	of	individual	 life-	history	traits.	
In	 comparison	 with	 classical	 statistical	 methods	 (Lamberton	 et	al.,	
2017),	 the	SSM	was	able	 to	differentiate	 life-	history	 traits	between	
parasite	 lines.	 This	 is	 likely	 because	 this	 SSM	method	 explicitly	 in-
corporates	 the	 observation	 process	 (i.e.,	 experimental	 design)	 that	
generated	the	data.	 In	contrast	to	our	hypothesis,	 in	the	absence	of	
praziquantel,	R	lines	did	not	exhibit	a	consistent	cost	compared	to	S	
lines	in	either	host.	Although	lower	adult	survival	was	observed	in	R	
lines,	 this	was	accompanied	by	higher	fecundity,	whilst	 the	negative	
trade-	off	between	adult	worm	survival	and	fecundity	was	seen	across	
all	three	parasite	lines	in	the	absence	of	praziquantel	treatment.	In	the	
intermediate	 host,	 there	were	 also	 no	differences	 between	parasite	
lines.	Life-	history	traits	of	other	S. mansoni	praziquantel-	resistant	lines	
have	been	also	been	shown	to	be	similar	to	praziquantel-	susceptible	
lines	in	other	laboratory	studies	(e.g.,	Cioli	and	Pica-	Mattoccia	(2003)	
and	others).	These	findings	suggest	that	there	are	no	consistent,	ob-
servable	costs	to	individual	life-	history	traits	measured	here	in	the	ab-
sence	of	treatment.
However,	 in	the	presence	of	drug	treatment,	R,	and	to	some	ex-
tent	RS,	had	altered	 life-	history	strategies	within	the	definitive	host.	
F IGURE  4 Sexual	life-	history	traits	and	trade-	offs	under	dose-	dependent	praziquantel	pressure.	For	each	S. mansoni	line,	susceptible	(S;	
left),	mixed	resistant	and	susceptible	(RS;	middle)	and	resistant	(R;	right),	and	praziquantel	(PZQ)	dose	(rows),	the	median	(with	95%	CIs)	survival	
(x-	axis)	and	fecundity	(y-	axis)	rates	are	shown	for	each	generation.	The	trade-	offs	between	these	traits	(black	line	and	associated	slope,	β)	were	
obtained	from	a	Poisson	GLM	of	the	posterior	distributions	of	survival	and	fecundity.	All	regressions	were	significant	with	p<.001,	except	R	low	
and	R	and	RS	high	PZQ.	p-	values	and	standard	deviations	shown	in	Appendix	S3	Table	S2
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A	negative	trade-	off	between	survival	and	fecundity	was	less	appar-
ent	in	R	lines	treated	with	both	the	low	and	high	praziquantel	and	RS	
lines	treated	with	the	high	dose.	Trade-	offs	are	less	likely	to	be	found	
when	resource	availability	and/or	allocation	 is	variable	 (Noordwijk	&	
de	Jong,	1986)	(Figure	5b).	Drug	treatment	could	modify	resource	allo-
cation	(Johnson	et	al.,	2007),	so	that	R	parasites	are	not	only	investing	
energy	in	survival	and	reproduction.	For	RS	parasites,	a	negative	trade-	
off	between	fecundity	and	survival	in	adult	worms	was	still	observed	
when	treated	with	lower	doses	of	praziquantel	(25	mg/kg).	However,	
this	trade-	off	was	altered	in	the	RS	line	when	the	higher	(50	mg/kg)	
praziquantel	dose	was	administered,	with	adult	worm	fecundity	barely	
decreasing	at	higher	adult	worm	survival.	This	latter	effect	appeared	to	
be	similar	to	the	effect	for	both	praziquantel	doses	in	the	R	line,	indi-
cating	a	complex	interaction	between	drug	susceptibility,	praziquantel	
dose	and	 resource	allocation.	There	was	no	 significant	difference	 in	
adult	worm	sizes	between	 lines	 (Lamberton	et	al.,	2017),	suggesting	
that	resource	allocation	towards	growth	could	not	explain	the	absence	
of	negative	trade-	offs	under	drug	pressure.
Praziquantel’s	exact	mechanism	of	action	is	unknown,	but	several	
studies	indicate	it	may	be	related	to	calcium	(Ca2+)	channels	and	teg-
ument	damage	 (Greenberg,	 2013).	Juvenile	worms	 are	not	 killed	by	
praziquantel,	and	it	is	only	after	they	reach	sexual	maturity	that	they	
are	 praziquantel-	susceptible	 (Cioli	&	Pica-	Mattoccia,	 2003).	A	 study	
has	 shown	 that	 juvenile	 worms	 increase	 transcription	 of	 stress	 re-
sponse	genes	that	may	counteract	Ca2+	influx	(Hines-	Kay	et	al.	2012),	
potentially	explaining	their	tolerance.	If	praziquantel	induced	a	similar	
level	of	stress	in	adult	worms	in	R	lines,	then	a	similar	stress	response	
may	be	predicted.	The	 loss	of	 a	 trade-	off	between	adult	worm	sur-
vival	and	fecundity	in	R	and	RS	lines	under	praziquantel	pressure	may	
indicate	that	R	parasites	still	have	the	ability	to	increase	transcription	
of	stress	response	genes	to	protect	against	praziquantel	and	that	this	
additional	 energy	 sink	may	 cloud	 trade-	offs	 between	 fecundity	 and	
survival.
Drug	pressure	has	increased	dramatically	since	just	2003	(Webster,	
Molyneux,	Hotez,	&	Fenwick,	2014)	but	is	still	currently	relatively	rare	
in	 the	 field,	with	 each	 person	 normally	 treated	 once	 a	year	 or	 less.	
Therefore,	an	alternative	explanation	for	why	resistant	parasites	have	
not	 yet	 become	more	widespread	 is	 that	 although	 R	 parasite	 lines	
will	 be	 able	 to	 establish	within	 a	 human,	 their	 lower	 overall	 fecun-
dity	makes	it	less	likely	that	“R”	genes	would	be	transmitted	onwards.	
The	existence	of	 such	 trade-	offs	could	be	critical	 to	how	resistance	
spreads,	particularly	given	WHO’s	recent	shift	from	morbidity	control	
to	elimination	as	a	public	health	problem	(WHO	2013)	and	the	planned	
increase	in	treatment	coverage,	frequency	and	dose	(moving	to	more	
community-	wide	 treatment	 rather	 than	school-	aged	children,	 twice-	
a-	year	 treatments,	at	potentially	a	60	mg/kg	dose).	Further	 research	
is	required	to	explore	the	range	of	trade-	off	responses	and	switches	
to	establish	whether	these	are	related	to	different	expression	profiles	
(Greenberg,	2013),	 stress	 response	genes	 (Hines-	Kay	et	al.	2012)	or	
other	genetic	or	epigenetic	factors.
Previous	work	has	documented	lower	cercarial	production	in	sev-
eral	 resistant	 lines	 (William	et	al.,	 2001).	Although	 the	R	 and	S	par-
asite	 lines	used	have	different	 susceptibilities	 to	praziquantel	 in	 the	
definitive	mouse	host	in vivo,	definitive	host	life-	history	traits	were	not	
correlated	with	traits	in	the	intermediate	host,	with	no	differences	ob-
served	between	parasite	lines	or	with	praziquantel	treatment.	This	was	
consistent	with	our	observation	that	direct	exposure	to	praziquantel	
has	a	stronger	influence	on	life-	history	parameters	than	parasite	line	
alone,	 indicating	 that	we	may	 be	 reporting	 phenotypic	 or	 inducible	
effects,	 rather	 than	 simply	 genotypic	 selection.	Our	model	 did	 nev-
ertheless	support	a	trade-	off	between	miracidia	infectivity	and	estab-
lishment	rate	with	mean	cercarial	shedding,	similar	to	that	observed	in	
the	definitive	host.	Establishment	 increased	across	the	experiments,	
reaching	nearly	1.0	in	G2	B. alexandrina.	The	increase	in	establishment	
rates	in	both	snail	species	may	reflect	local	adaptation	to	the	partic-
ular	laboratory	strains.	Faster	adaptation	within	B. alexandrina	than	in	
F IGURE  5 Life-	history	traits	quantify	an	organism’s	investment	into	components	of	fitness,	such	as	reproduction	(y-	axis)	and	survivorship	
(x-	axis).	(a)	There	are	recognized	trade-	offs	between	life-	history	traits	(solid	curve),	so	that	an	increase	in	fecundity	is	associated	with	decreased	
survivorship	(orange)	or	conversely	higher	survivorship	leads	to	lower	fecundity	(green).	These	life-	history	trade-	offs	arise	from	limited	resources	
available	for	an	organism’s	growth,	reproduction	and	survivorship.	(b)	However,	trade-	off	curves	can	shift	as	resource	(energy)	availability	for	
certain	traits	change—this	may	be	due	to	other	resource	allocation	needs	in	the	organism	or	a	decline	in	resource	availability.	When	this	occurs,	
negative	trade-	offs	are	difficult	to	observe	and	a	decline	in	one	trait	(orange)	may	not	be	compensated	by	a	second	observed	trait	(green).	
[Figure	adapted	from	work	by	Noordwijk	and	de	Jong	(1986)]
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B. glabrata	may	reflect	its	role	as	their	natural	host	even	in	laboratory	
conditions.	Additionally,	 the	 larger	 variation	 in	 estimates	 associated	
with	B. alexandrina	may	be	due	to	a	larger	genetic	variability	within	the	
host	species	compared	with	the	laboratory-	adapted	B. glabrata.
In	 the	 snail	 host,	 there	were	 few	differences	observed	between	
lines	and	no	effect	of	indirect	praziquantel	treatment	on	parasite	life	
histories.	 Cercarial	 production	 was	 not	 different	 between	 R	 and	 S	
parasite	 lines;	however	 in	early	generations	of	RS,	 cercarial	 produc-
tion	was	higher	than	S	and	R	individually.	Overall,	the	mixed	RS	lines	
also	demonstrated	 the	highest	 establishment	 and	 survival	 across	 all	
generations,	relative	to	their	single-	line	counterparts,	supporting	pre-
vious	findings	 (Lamberton	et	al.,	2017).	 In	a	natural	system,	a	mixed	
infection	may	be	more	likely	to	result	in	increased	in	fitness,	if	random	
mating	occurs.	As	Schistosoma	 species	 rapidly	 lose	genetic	variation	
when	passaged	in	the	laboratory	(Gower	et	al.,	2007;	Stohler,	Curtis,	
&	Minchella,	2004),	the	increased	fitness	of	RS	may	be	explained	by	
an	outbreeding	 effect,	 through	 increased	 genetic	 diversity,	 of	 these	
two	potentially	bottlenecked	inbred	laboratory	S	and	R	strains,	partic-
ularly	in	the	first	generation.	Some	of	the	variability	in	the	traits	mea-
sured	in	these	RS	lines	could	also	be	explained	by	nonrandom	mating	
and	 facilitation	 and/or	 competition	 between	R	 and	 S,	 or	 a	 complex	
combination	of	all	of	these.	In	the	trade-	off	analyses	discussed	above,	
survival	and	fecundity	trade-	offs	observed	in	the	co-	infected	RS	line	
with	increased	treatment	fall	between	R	and	S	lines,	correlating	with	a	
mid-	level	of	drug	resistance.
Although	we	 used	 subcurative	 doses	 of	 praziquantel	 (25	mg/kg	
and	50	mg/kg	in	a	rodent	model	system),	this	level	of	treatment	may	
be	more	relevant	to	actual	MDA	campaigns	than	previously	thought.	
We	deliberately	chose	subcurative	doses,	to	enable	us	to	continue	the	
life	 cycle	 in	 the	 treated	 selected	 lines,	 as	 this	would	not	have	been	
possible	 if	 all	 S	 parasites	 had	 died	 with	 treatment.	 Cure	 rates	 for	
human	 treatment	are	not	100%	 (Doenhoff,	Cioli,	&	Utzinger,	2008),	
and	therefore,	our	scenario	where	some	worms	survive	treatment	was	
aimed	to	be	representative	of	natural	systems.	Indeed,	there	is	recent	
evidence	that	underdosing	may	be	widespread	in	children	due	to	phar-
macokinetic	 differences	with	 adults	 on	whom	 the	 drug	was	 initially	
trialled	 (Bustinduy	 et	al.,	 2016;	 Olliaro,	 Delgado-	Romero,	 &	 Keiser,	
2014).	 As	 the	 majority	 of	 national	 treatments	 are	 administered	 to	
children	(WHO	2016),	modifications	to	life-	history	trade-	offs	seen	in	
our	experiment	may	also	appear	in	subcurative	treatments	in	humans.	
Declines	in	fecundity	estimated	here	strongly	support	other	empirical	
studies	(Lamberton,	Kabatereine,	Oguttu,	Fenwick,	&	Webster,	2014),	
but	whether	trade-	offs	between	fecundity	and	survival	are	modified	
in	resistant	parasites	in	natural	populations	remains	an	open	question.
Whilst	the	experiment	was	designed	to	investigate	trade-	offs	that	
would	be	nearly	impossible	to	observe	in	the	field,	there	were	a	few	
limitations	 of	 the	 design.	We	 saw	no	differences	 in	 definitive	 hosts	
across	 generations	 but	 this	 may	 be	 due	 to	 the	 lower	 sample	 sizes	
(n	=	4)	 for	each	treatment	group	per	generation,	 in	comparison	with	
the	larger	sample	sizes	for	snail	hosts	(n	=	50	per	treatment	group).	In	
addition,	the	R	and	S	parasite	lines	have	been	passaged	in	the	labora-
tory	for	over	a	decade	and	may	have	lost	significant	genetic	diversity.	
Although	 the	 two	 strains	 that	were	 used	 (MOC-	S	 and	 EE2-	R)	 have	
significantly	different	susceptibilities	to	praziquantel	and	the	levels	of	
susceptibility	are	stable	over	laboratory	passages	even	in	the	absence	
of	 drug	 treatment	 (Sabra	&	Botros,	 2008;	William	 et	al.,	 2001),	 po-
tential	costs	may	have	been	reduced	under	previous	laboratory	selec-
tion.	 In	 addition,	 although	EE2-	R’s	 stability	 is	 important	 to	 compare	
between	a	susceptible	and	resistant	parasite,	it	might	be	that	the	sta-
bility	 is	 inherently	 linked	 to	not	having	high	costs	of	 resistance.	For	
example,	 those	which	 lost	 their	 resistance	 rapidly	 in	 the	 laboratory,	
or	could	not	be	successfully	isolated	in	the	laboratory,	may	have	had	
higher	costs	initially,	minimizing	our	ability	to	detect	them.	Our	mod-
els,	however,	did	detect	subtle	differences	in	the	trade-	offs	between	
individual	traits	and	how	these	changed	with	treatment,	particularly	in	
the	R	lines,	which	were	not	detected	using	statistical	methods	alone	
(Lamberton	et	al.,	2017).
5  | CONCLUSIONS
Few	empirical	data	are	available	on	the	costs	of	drug	resistance.	Here,	
we	demonstrate	the	complexity	of	quantifying	costs	and	the	impor-
tance	 of	 monitoring	 not	 just	 simple	 trait-	specific	 life	 histories,	 but	
within	and	between	host	trade-	offs.	We	observed	the	expected	prazi-
quantel	dose-	dependent	reduction	in	S. mansoni	adult	worm	survival	
and	establishment	in	all	parasite	lines.	In	addition	to	the	survival	and	
fecundity	 effects,	 there	was	 evidence	 of	 important	 changes	 in	 life-	
history	trade-	offs	with	praziquantel	treatment	in	R	lines.	The	shape	of	
the	trade-	off	between	fecundity	and	survival	in	R	and	S	adult	worms	
suggested	divergent	strategies	with	increasing	 in vivo	drug	pressure.	
These	 results	 highlight	 the	 importance	 of	 monitoring	 multiple	 life-	
history	 traits	 and	 the	 trade-	offs	between	 them	as	well	 as	 the	com-
plexity	in	interpreting	them.	Our	study	also	highlights	the	complexity	
of	life-	history	traits	within	and	between	life	cycle	stages	and	experi-
mental	design,	 for	monitoring	evolutionary	processes	even	within	a	
controlled	laboratory	environment.	Mass	drug	administration	against	
schistosomiasis	 at	 the	 current	 scale	 and	 frequency	 raises	 concerns	
about	 the	emergence	of	drug	 resistance	 in	 the	parasites	 (Bergquist,	
Utzinger,	 &	 Keiser,	 2017;	 Botros	 &	 Bennett,	 2007;	Webster	 et	al.,	
2014),	 but	 such	detailed	 studies	would	 be	 impossible	 to	 achieve	 in	
the	 field	 under	 natural	 (human	 definitive	 host)	 conditions.	 Our	 re-
sults	thereby	provide	important	insights	and	have	theoretical	and	ap-
plied	implications	and	applications	for	future	schistosomiasis	control	
programmes	 and	 for	 other	 host–parasite	 treatment	 programmes	 in	
general.
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